Login Preferences
About News Publications Statistics Downloads API Guide License How to use Preferences
bn:00443147n
Noun Concept
Categories: Enantiopure drugs, Treatment and management of attention deficit hyperactivity disorder, Antiparkinsonian agents, Phenethylamines, Monoamine oxidase inhibitors
EN
selegiline  (−)-selegiline  (±)-deprenyl  Selegiline Hydrochloride  Anipryl
EN
Selegiline, also known as L-deprenyl and sold under the brand names Eldepryl, Emsam, Selgin, among other names, is a medication which is used in the treatment of Parkinson's disease and major depressive disorder. Wikipedia
Definitions
Relations
Sources
EN
Selegiline, also known as L-deprenyl and sold under the brand names Eldepryl, Emsam, Selgin, among other names, is a medication which is used in the treatment of Parkinson's disease and major depressive disorder. Wikipedia
Chemical compound, pharmaceutical drug Wikidata
IS A
compound
medicine
selegiline
Saturated and unsaturated compounds
HAS INSTANCE
selegiline
D-Deprenyl
DIFFERENT FROM
selegiline
MEDICAL CONDITION TREATED
attention deficit disorder
schizophrenia
paralysis agitans
early-onset Alzheimer's disease
PREGNANCY CATEGORY
Australian pregnancy category B2
SUBJECT HAS ROLE
monoamine oxidase inhibitor
Antiparkinson
neuroprotective agent
Wikipedia
EN
selegiline
Wikidata
EN
(±)-deprenyl, (−)-selegiline
Wikipedia Redirections
EN
Anipryl, Apo-Selegiline, ATC code N04BD01, ATCvet code QN04BD01, ATCvet code QN06AX90, Carbex, deprenyl, Eldepryl, Emsam, Gen-Selegiline, Jumex (drug), L-Deprenyl, L-deprenyl, Novo-Selegiline, Nu-Selegiline, Sd Deprenyl, Selegeline, Selegilin, Selegiline hydrochloride, Selegiline Hydrochloride, Seligiline, Zelapar
Wikidata Alias
EN
L-Deprenalin, L-deprenyl, Selegilina, selegiline, Selegiline, Selegilinum, (−)-selegiline

Please note that, in order to improve your browsing experience on this website, BabelNet® uses various types of cookies, including: browsing functionality, performance and statistical cookies.

By continuing to browse the site you are agreeing to our use of cookies. OK

License